Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis

PURPOSE: To compare the efficacy and safety between pyrotinib (Pyr) and trastuzumab emtansine (T-DM1) in pre-treated human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) patients. METHODS: A comprehensive literature search of the PubMed, EMBASE, and Web of Science...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Hao, Huang, Wenfa, Liu, Yaxin, Pei, Wendi, Li, Huiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127838/
https://www.ncbi.nlm.nih.gov/pubmed/34012912
http://dx.doi.org/10.3389/fonc.2021.608781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127838/
https://www.ncbi.nlm.nih.gov/pubmed/34012912
http://dx.doi.org/10.3389/fonc.2021.608781

Ejemplares similares